The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market : Market Research Report

The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market

Published: Feb. 26, 2009 - 82 Pages

1. Executive Summary
2. Global - Diabetes Overview: 2.1 Diabetes Prevalence; 2.2 Impaired Glucose Tolerance (IGT); 2.3 Global - Top 10 Countries Performance On; 2.4 Diabetes and Obesity Interlinked
3. Global Market Analysis: 3.1 Global Diabetes Prevalence; 3.2 Global Diabetes Drugs Market (Past, Present & Future Scenario); 3.3 Global Insulin Market (Past, Present & Future Scenario)
4. Top 10 Countries Performance On: 4.1 United States; 4.2 China; 4.3 India; 4.4 Brazil; 4.5 Russia; 4.6 Germany; 4.7 Pakistan; 4.8 Mexico; 4.9 Egypt; 4.10 Japan
5. Key Players: 5.1 Novo Nordisk A/S; 5.2 Sanofi-Aventis; 5.3 Takeda Pharmaceutical Company Limited; 5.4 GlaxoSmithKline plc; 5.5 Servier; 5.6 Bayer AG; 5.7 Merck & Co.; 5.8 Eli Lilly and Company; 5.9 Amylin Pharmaceuticals, Inc.; 5.10 Merck KGaA
List of Figures:: Figure 2 1: Global - By Region Number of People with Diabetes, (20-79 age group) (in Millions) 2007 & 2025; Figure 2 2: Global - By Region Prevalence of Diabetes*, (20-79 age group) (in Percent) 2007 & 2025; Figure 2 3: Global - By Region People with Diabetes in different age group (20-39) (40-59) (60-79) (in Millions), 2007; Figure 2 4: Global - By Region Number of People with Impaired Glucose Tolerance (20-79 age group) (in Millions) 2007 & 2025; Figure 2 5: Annual Health Expenditure for Diabetes (ID) vs Persons with Diabetes in the 25 Countries with the Largest Numbers of Persons with Diabetes in 2007; Figure 2 6: Global - By Region Number of Deaths attributable to Diabetes (20-79 age group) (in Millions) 2007; Figure 2 7: Global - By Region Overweight and Obesity among School-age Children (5-17 Years), 2003; Figure 3 1: Global - Diabetes Drug Market (in Billions US$), 2005 - 2007E; Figure 3 2: Global - Diabetes Drug Market (in Billions US$), 2008 - 2010; Figure 3 3: Global - Insulin Market (in Billion US$), 2005 - 2007; Figure 3 4: Global - Insulin Market (in Billion US$), 2008 - 2012; Figure 3 5: Global - By Region Usage of Types of Insulin (Rapid-and fast-acting, Long-and intermediate-acting, Premix, Analogue, U100, Animal), (in Percent), 2005; Figure 3 6: Global - Ukraine, China, Pakistan, Argentina, Brazil & Uruguay - Uses of Animal Insulin (in Percent), 2005; Figure 3 7: Global - Egypt, Hungry, Ukraine, Bangladesh, India, China & Indonesia - Uses of Non-U100 Insulin (in Percent), 2005; Figure 4 1: US - Number of Diagnosed Diabetes Patients (in Million), 2003 - 2007; Figure 4 2: US - Direct and Indirect Cost of Diabetes (in Billion US$), 2007E; Figure 4 3: US - Glucose Strips Markets (in Billion US$), 2006 - 2013F; Figure 4 4: US - Diabetes Drug Market (in Billion US$), 2001 - 2007; Figure 4 5: US - Forecast for Diabetes Drug Market (in Billion US$), 2008 - 2010; Figure 4 6: US - Insulin Market (in Billion US$), 2003 - 2007E 37; Figure 4 7: US - Forecast for Insulin Market (in Billion US$), 2008 - 2010; Figure 4 8: China - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 9: China - Anti-diabetic Drug Market (in Million Yuan), 2006 - 2007; Figure 4 10: China - Forecast for Anti-diabetic Drug Market (in Million Yuan), 2008 - 2010; Figure 4 11: China - Insulin & Analogue Market (in Million Yuan), 2006 - 2007; Figure 4 12: China - Forecast for Insulin & Analogue Market (in Million Yuan), 2008 - 2010; Figure 4 13: India - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 14: India - Anti-diabetic Drug Market (in Crore Rs), 2002 - 2007; Figure 4 15: India - Forecast for Anti-diabetic Drug Market (in Crore Rs), 2008 - 2010; Figure 4 16: India - Share of Human Insulin Market, Animal Insulin Market & Oral Anti-Diabetic Market (in Percent), 2003 & 2007; Figure 4 17: India - Insulin Market (in Crore Rs), 2003 - 2007; Figure 4 18: India - Forecast for Insulin Market (in Crore Rs), 2008 - 2010; Figure 4 19: India - Uses of Insulin Syringes, Cartridges and Pen Systems (in Percent), 2005; Figure 4 20: Brazil - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 21: Brazil - Oral Anti-diabetic Drug Market (in Million US$), 2000, 2001, 2007E; Figure 4 22: Brazil - Forecast for Oral Anti-diabetic Drug Market (in Million US$), 2008 - 2010; Figure 4 23: Brazil - Insulin Market (in Million US$), 2000, 2001, 2003, 2007E; Figure 4 24: Brazil - Forecast for Insulin Market (in Million US$), 2008 - 2010; Figure 4 25: Russia - Number of Diabetes Patients (in Million), 2005 - 2007; Figure 4 26: Russia - Insulin Market (in Million US$), 2002, 2005 - 2007E; Figure 4 27: Russia - Forecast for Insulin Market (in Million US$), 2008 - 2010; Figure 4 28: Germany - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 29: Germany - Insulin Market (in Million US$), 2004 - 2007; Figure 4 30: Germany - Forecast for Insulin Market (in Million US$), 2008 - 2010; Figure 4 31: Pakistan - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 32: Mexico - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 33: Mexico - Insulin Market (in Million US$ & Percent), 2004; Figure 4 34: Egypt - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 35: Japan - Number of Diabetes Patients (in Million), 2003 - 2007; Figure 4 36: Japan - Insulin Market (in Million US$), 2005 - 2007; Figure 4 37: Japan - Forecast for Insulin Market (in Million US$), 2008 - 2010
List of Tables:: Table 2 1: Global - Total Adult Population, Impaired Glucose Tolerance Population & Comparative Prevalence, (20-79 age group) (in Billions, Millions and Percent) respectively 2007 & 2025; Table 2 2: Global - Top 10 Countries Number of People with Diabetes (20-79 age group) (in Millions) 2007 & 2025; Table 2 3: Global - Top 10 Countries in Prevalence of Diabetes (20-79 age group) (in Percent) 2007 & 2025; Table 2 4: Global - Top 9 Anti-obesity (systemic) Brand Sales (in Millions), Market Share & Percentage Change, November 2007 to October 2008; Table 3 1: Global - Number of People with Diabetes & Prevalence (20-79 age group) (in Millions & Percent) 2007 & 2025; Table 3 2: Global - Top 10 Oral Anti-diabetics Market Share & Fixed-rate Growth (in Percent), July 2006 - June 2007; Table 3 3: Global - Top 8 Diabetes (Non-Insulin) Brand Sales (in Millions), Market Share & Percentage Change, October 2007 - October 2008; Table 4 1: US - Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 - 2025; Table 4 2: China - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 3: India - Forecast for Number of Diagnosed Diabetes Patients (in Million), 2008 - 2025; Table 4 4: Brazil - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 5: Russia - Forecast for Number of Diabetes Patients (in Millions), 2008 - 2025; Table 4 6: Germany - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 7: Pakistan - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 8: Mexico - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 9: Egypt - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 4 10: Japan - Forecast for Number of Diagnosed Diabetes Patients (in Millions), 2008 - 2025; Table 5 1: Novo Nordisk A/S - Financial Overview (in Million US$), 2006-2008; Table 5 2: Sanofi-Aventis - Financial Overview (in Million US$), 2005-2007; Table 5 3: Sanofi-Aventis - Financial Overview (in Million US$), 2004-2006; Table 5 4: Sanofi-Aventis - Financial Overview (in Million US$), 2005-2007; Table 5 5: Bayer AG- Financial Overview (in Million US$), 2005-2007; Table 5 6: Merck & Co. - Financial Overview (in Million US$), 2005-2007; Table 5 7: Eli Lilly and Company - Financial Overview (in Million US$), 2005-2007; Table 5 8: Amylin Pharmaceuticals, Inc. - Financial Overview (in Million US$), 2005-2007; Table 5 9: Merck KGaA - Financial Overview (in Million US$), 2005-2007

Abstract

About the Report

The Renub Research report titled “The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market” gives a detailed analysis on the global diabetes market. This report investigates the top 10 countries: diabetes prevalence, diabetes drug market and insulin market. It also provides a description of the sales and market share of top 10 brands in anti-obesity drug and diabetes drug market globally. This report talks about the prevalence of Impaired Glucose Tolerance (IGT) globally, 20 countries annual health expenditure on diabetes, death due to type 1 and type 2 diabetes globally.

Market Overview

In recent year’s diabetes drug market and insulin market has shown remarkable growth. This growth is mostly driven by increasing prevalence of diabetes globally and easily availability of insulin in other countries due to its access at an affordable price. The diabetes prevalence is increasing due to changing food habits in the western world leading to obesity.

As the prevalence of obesity and related diseases (diabetes) has increased, so have the sales of drugs to treat them. Top 9 brands of anti-obesity drugs have done sales of more than US$ 100 Million by November 2007 to October 2008. Whereas, top 8 diabetes drug made a sale of more than US$ 5 Billion from the period of October 2007 to October 2008.
Although the works are going on to make the oral-pills an alternative for insulin but at present none of the systems have mimics the physiology of insulin secretion. So it is expected that insulin market will keep on growing to reach US$ 15 Billion by 2012. In future Insulin demand will be driven by countries such as US, China, India, Brazil, Russia and Germany.

Countries Analyzed

World Top 10 diabetic populace countries performances on: diabetes prevalence, diabetes drugs market and insulin market (their past, present and future forecast) have been analyzed in this report. The countries covered in this repot are as follows: United States (US), China, India, Brazil, Russia, Germany, Pakistan, Mexico, Egypt and Japan.

Research Highlights

By 2025 it is expected that India, China and US will be the first, second and third most diabetic populace country.
In 2005 use of Non-U100 insulin was very popular in India, Ukraine and Egypt its use was more than 50 percent.
Anti-obesity drug Meridia and Phentermine Hcl combined corner a market share of more than 65 percent globally from the period of November 2007 to October 2008.
Anti-diabetic drug Actos (product of Takeda) control the highest market share of 40.5 percent globally from the period of October 2007 to October 2008.
Diabetes drug Actos sale was highest it was more than twice the sale of its nearest competitor Januvia for the period of October 2007 to October 2008.
Indian diabetic drug market is expected to be more than Rs. 3,200 Crore by 2010.
Human insulin market in India has been increased to 30 percent in 2007 compared to 25 percent in 2003.
In India delivery of insulin using cartridges and pen systems is less than 20 percent but it is growing by 35 percent annually.
China insulin and analogue market grow by 55.8 percent in the year 2007 compared to 2006.
Russia insulin market is expected to cross the mark of US$ 600 Million by 2010.
In 2004 Mexico insulin market was just 1 percent of its total pharmaceutical market.

Key Players

Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Servier, Bayer AG, Merck & Co., Eli Lilly and Company, Amylin Pharmaceuticals, Inc., Merck KGaA

Data Sources

The information has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, Government Agencies and Trade associations.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market

Table of Contents

Abstract